VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
STRO
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
STROSutro Biopharma, Inc.
$8.50$82M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
STRO logo

Sutro Biopharma, Inc.

STRO
NASDAQ · Oncology Biotech
$8.50
At close - Nov 18, 4:00 PM EST - USD
Market Cap$82M
P/E-0.9x
52W High$43.85
Volume276.84K
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
MARKET ACTION

STRO price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

4/12 Beats

EPS beat 4 of last 12 quarters

02

Valuation risk

-104% Peers

P/E is 104% below peer median

03

Market leadership

RS 15 · Lag

Laggard (Underperforming 85% of market)

04

Weak Trend

Below 200DMA

Price < 200DMA

Next CatalystEstimated earnings · Feb 12

Market performance

Price History →

Trailing total returns as of 11/19/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
STRO-22.45%
S&P 500 (^GSPC)+6.88%
1-Year Return
STRO-4.49%
S&P 500 (^GSPC)+10.62%
3-Year Return
STRO-69.31%
S&P 500 (^GSPC)+53.58%
5-Year Return
STRO-95.30%
S&P 500 (^GSPC)+53.42%

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
$102M+65.2% YoY
Net income FY25
-$191M+16.0% YoY
Free cash flow FY25
-$179M+8.1% YoY
Operating margin FY25
-102.4%+281.9 pts YoY
ROIC (FY25)-
Avg ROIC 5Y-37.4%
ROE (FY25)-
Piotroski Score3 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate4/12 (33%)
Revenue Beat Rate8/12 (73%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q4 2026Latest
Nov 12, 2026
-$1.90-15.9%
vs -$1.64
—
vs $14M
Q3 2026
Aug 12, 2026
-$2.33-6.4%
vs -$2.19
$10M-17.7%
vs $12M
Q2 2026
May 14, 2026
-$2.94-26.7%
vs -$2.32
$15M+63.3%
vs $9M
Q2 2026
Mar 23, 2026
-$5.29+35.2%
vs -$8.16
$12M+25.8%
vs $9M
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

4 Stories
GlobeNewsWire·6d ago
Sutro Biopharma Reports Third Quarter 2026 Financial Results and Business Highlights

– STRO-004, TF-targeting ADC, Phase 1 STRIVE-01 study advancing; next clinical update and initiation of expansion cohorts planned first half of 2027 –

Zacks Investment Research·Nov 4, 2026
Here's Why Sutro Biopharma (STRO) is Poised for a Turnaround After Losing 34.2% in 4 Weeks

The heavy selling pressure might have exhausted for Sutro Biopharma (STRO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

GlobeNewsWire·Nov 4, 2026
Sutro Biopharma to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that management will participate in several upcoming investor conferences.

Zacks Investment Research·Nov 3, 2026
Down 39.8% in 4 Weeks, Here's Why Sutro Biopharma (STRO) Looks Ripe for a Turnaround

Sutro Biopharma (STRO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Filtered for Sutro Biopharma, Inc.More Headlines
04

Compare before deciding

Benchmark STRO against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Sutro Biopharma, Inc. (STRO)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
STRO logoSTROSutro Biopharma, Inc.Current
$8.50$82.26M-0.9165.18%-344.22%——
RCUS logoRCUSArcus Biosciences, Inc.
$15.76$1.98B-4.51-4.26%-445%-90.04%—
BOLT logoBOLTBolt Biotherapeutics, Inc.
$5.10$9.8M-0.390.07%-1027.93%-154.11%—
NKTR logoNKTRNektar Therapeutics
$34.42$1.18B-6.64-43.89%-339.67%-29.31%—
AGIO logoAGIOAgios Pharmaceuticals, Inc.
$29.68$1.77B-4.7548.03%-264.76%-34.63%—
MGNX logoMGNXMacroGenics, Inc.
$1.97$125.22M-2.440.78%-45.37%-142.22%—

Compare STRO vs Peers

Sutro Biopharma, Inc. (STRO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs RCUS

Most directly comparable listed peer for STRO.

Scale Benchmark

vs ABBV

Larger-name benchmark to compare STRO against a more recognizable public peer.

Peer Set

Compare Top 5

vs RCUS, BOLT, NKTR, AGIO

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

STRO SEC Filings & Documents

Sutro Biopharma, Inc. (STRO) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Aug 12, 2026·SEC

Material company update

Jun 8, 2026·SEC

Material company update

May 14, 2026·SEC

10-K Annual Reports

3
FY 2026

Mar 23, 2026·SEC

FY 2025

Mar 13, 2025·SEC

FY 2024

Mar 25, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

Aug 12, 2026·SEC

FY 2026

May 14, 2026·SEC

FY 2025

Nov 6, 2025·SEC

Get notified when STRO posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

STRO Frequently Asked Questions

Sutro Biopharma, Inc. (STRO) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Sutro Biopharma, Inc.'s revenue?

Sutro Biopharma, Inc. (STRO) reported $45.1M in revenue over the trailing twelve months. Revenue was $102.5M in fiscal year 2025. That is 72% more than the $59.7M of fiscal year 2016.

How fast is Sutro Biopharma, Inc. growing?

Sutro Biopharma, Inc. (STRO) revenue fell by 57.3% over the trailing twelve months, compared with the twelve months before.

Is STRO profitable?

No. Sutro Biopharma, Inc. (STRO) reported a net loss of $155.3M over the trailing twelve months.

Dividend & Returns
What is Sutro Biopharma, Inc.'s free cash flow?

Sutro Biopharma, Inc. (STRO) had negative free cash flow of $129.8M over the trailing twelve months.

What if you invested $1,000 in STRO back in 2016?

Total return calculator · dividends reinvested · 10+ years of data

See returns →